The Patent Trial and Appeal Board (PTAB) has delivered a significant ruling in favor of Pfizer and BioNTech, invalidating two patents held by Moderna. These patents were related to Moderna’s Spikevax COVID-19 vaccine. This decision represents a substantial development in the ongoing legal disputes concerning COVID-19 vaccine patents, where Pfizer and BioNTech faced accusations of patent infringement by Moderna.
The invalidation of the patents by the PTAB may influence the dynamics of the vaccine market, potentially affecting both companies’ strategies and competitive positioning. This ruling underscores the complexities and challenges faced by pharmaceutical companies as they navigate intellectual property rights in the rapidly evolving landscape of vaccine development.
Further details about the ruling can be read in the original article on Law360.